Life Sciences
Domantis Limited, The Medical Research Council of the UK
www.domantis.com
Domantis is a drug discovery and development company exploiting the multiple therapeutic applications of Domain Antibodies. Domantis has begun over a dozen therapeutic discovery programs which the company expects to progress through partnerships.
Glycoform Limited, University of Oxford
www.glycoform.co.uk
Glycoform is a biotechnology company dedicated to the design and development of novel drug delivery systems and improved protein therapeutics using it’s novel Lectin-directed Enzyme Activated Pro-drug Therapy platform (LEAPT).
Oxford Biosensors is developing novel low complexity hand-held diagnostic devices for primary healthcare and the consumer markets. This platform technology is initially focused on measuring a patients risk of acute cardiac disease.
Oxitec Limited, University of Oxford
www.oxitec.com
Oxitec is a biotechnology company formed in August 2002 to communicate its novel method of biological insect control. Oxitec's core proprietary technology, known as RIDL™ based on the research of Luke Alphey and colleagues in the Department of Zoology.
Oxxon Therapeutics™ Incorporated, University of Oxford
www.oxti.com
Oxxon Therapeutics™ is a biotechnology company developing novel immunotherapeutics, based on its proprietary Heterologous PrimeBoost (PrimeBoost) approach, for the treatment of chronic infectious diseases and cancer. (Oxxon was founded in 1999 by a group of internationally renowned immunologists.)
Prolysis Limited, University of Oxford
www.prolysis.co.uk
Prolysis is a research and development company focused on the creation of medicines to address the spreading crisis of antibiotic resistance to hospital and community aquired infections. By exploiting unique insights into bacterial cell biology Prolysis is able to create the new broad-spectrum antibiotics that are urgently needed.
ReOx Limited, University of Oxford
www.reox.co.uk
ReOx is a drug discovery company that aims to build on the primary research of the founding academics to develop novel treatments for disease by controlling the activity of hypoxia inducible factor (HIF).
Surface Therapeutics is built on the results of two decades of research into the genetics of eczema and asthma. Having access to a substantial intellectual property portfolio has allowed them to identify several novel targets for therapy. These patents have also established a dominant position in DNA diagnostics for allergic disease.
ThromboGenics Limited, University of Leuven
www.thrombogenics.com
ThromboGenics is focused on the discovery and development of biotherapeutics for treatment of vascular diseases (including cardiovascular, cerebrovascular and peripheral vascular disease). The Company's founder and CEO is Désiré Collen, M.D., Ph.D., a world-renowned expert in cardiovascular disease and discoverer of t-PA.
Zyentia Limited, University of Cambridge
www.zyentia.com
Zyentia is a company operating in the fields of protein misfolding and human disease. Zyentia main focus of interest is on protein conformational diseases, although its portfolio also includes IP from the areas of novel peptide therapeutics and biomaterials.
Physical Sciences
Nanotecture Limited, University of Southampton
www.nanotecture.co.uk
Nanotecture was created with the objective of commercialising a patented, bottom-up nano-materials technology. Their technology allows them to create mesoporous metal and metal oxide films using both liquid crystal templated electro deposition and liquid crystal templated chemical deposition techniques. Nanotecture is focused on using this technology for power sources, filtration / separation media and sensors.
Offshore Hydrocarbon Mapping Limited, University of Southampton
www.ohmsurveys.com (AIM: OHM)
Offshore Hydrocarbon Mapping of Aberdeen provides active source electromagnetic (EM) services to the offshore oil industry. OHM's team of scientists and engineers has many years experience with EM to detect the presence of hydrocarbon deposits.
Plasso Limited , University of Sheffield
www.plasso.co.uk
Plasso is an advanced surface engineering company founded in 2003, based upon fifteen years of research at the University of Sheffield's world-leading Engeneering Materials Department. They provide tailored coatings to satisfy a new and growing demand for advanced, functional surfaces in life sciences research, diagnostics, biosensors and microfluidics.
Stratophase Limited, University of Southampton
www.stratophase.com
Stratophase, is developing new ways to create, connect and control light, increasing its intensity and changing its color applicable to the design and fabrication of periodically-poled lithium niobate (PPLN) and other micro-engineered crystal structures. The company uses its propriety technology to deliver optical solutions to equipment manufacturers, component manufacturers and end users in the areas of lasers, biophotonics, sensing and telecoms.
